Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3654123 | 0.81 | CNR2 (0.60) | CNR2MAPK14LMNAMAPT | |
| SCHEMBL10066902 | 0.76 | CNR2 (0.56) | CNR2MAPT | |
| SCHEMBL14299985 | 0.76 | CNR2 (0.56) | CNR2MAPK14 | |
| SCHEMBL774473 | 0.74 | CNR2 (0.52) | CNR2 | |
| SCHEMBL12827709 | 0.73 | CNR2 (0.46) | CNR2MAPK14LMNAMAPT | |
| SCHEMBL14299743 | 0.73 | CNR2 (0.53) | CNR2MAPK14MAPT | |
| SCHEMBL12753875 | 0.72 | CNR2 (0.39) | CNR2 | |
| SCHEMBL12827538 | 0.71 | CNR2 (0.48) | CNR2LMNA | |
| SCHEMBL3653682 | 0.65 | CNR2 (0.58) | CNR2SMN1; SMN2MAPK14LMNAMAPT | |
| SCHEMBL1621020 | 0.64 | CNR2 (0.67) | CNR2MAPK14LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885NR1H2 54/4885SMN1; SMN2 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.